Suppr超能文献

非甾体抗炎药(NSAIDs)在婴儿中的疗效和安全性:对过去 20 年文献的综合回顾。

Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

机构信息

Pediatric Cardiology and Congenital Heart Diseases, Centre for Child and Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.

Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.

出版信息

Paediatr Drugs. 2022 Nov;24(6):603-655. doi: 10.1007/s40272-022-00514-1. Epub 2022 Sep 2.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.

摘要

非甾体抗炎药(NSAIDs)在全球范围内广泛用于婴儿、儿童和青少年;然而,尽管有足够的证据表明 NSAIDs 对儿童和青少年有益,但婴儿的综合数据仍然缺乏。本综述总结了目前关于婴儿使用的各种 NSAIDs 的安全性和疗效的现有知识,其中包括布洛芬、右旋布洛芬、酮洛芬、氟比洛芬、萘普生、双氯芬酸、酮咯酸、吲哚美辛、尼氟酸、美洛昔康、塞来昔布、帕瑞昔布、罗非昔布、乙酰水杨酸和尼美舒利。NSAIDs 的疗效已在各种疾病中得到证实,如发热和疼痛。NSAIDs 也是儿科炎症性风湿病等抗炎治疗的主要支柱。关于大多数 NSAIDs 在婴儿中的安全性,可用数据有限。药物不良反应可能是肾、胃肠、血液学或免疫性的。由于 NSAIDs 是儿科人群中最常使用的药物之一,因此可以在正常临床常规中进行安全性和疗效研究,即使是在婴儿中。应使用可用的数据源(如电子病历)进行安全性和疗效分析。在更大的范围内,应使用特定于儿童的方法评估现有的数据源(如药物不良反应计划/网络、自发国家报告系统和电子病历),以检测与特定儿科年龄组或疾病实体相关的安全信号。为了提高 NSAIDs 在婴儿中的安全性,需要以最低的适合年龄或体重的剂量开始治疗。应定期评估治疗持续时间和药物使用量,并遵循制造商或专家委员会规定的最大剂量限制和其他建议。治疗非慢性疾病(如发热和急性(术后)疼痛)应尽可能缩短。患有慢性疾病的患者应定期监测 NSAIDs 的可能不良反应。

相似文献

7
10
Nonopioid drugs for pain.用于止痛的非阿片类药物。
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40.

引用本文的文献

本文引用的文献

9
Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis.尼美舒利致肝毒性:系统评价和荟萃分析。
PLoS One. 2019 Jan 24;14(1):e0209264. doi: 10.1371/journal.pone.0209264. eCollection 2019.
10
Safety Issues of Pharmacological Acute Pain Treatment in Children.儿童药理学急性疼痛治疗的安全性问题。
Clin Pharmacol Ther. 2019 May;105(5):1130-1138. doi: 10.1002/cpt.1358. Epub 2019 Mar 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验